BPD Research
Long/short equity

Threshold Pharmaceuticals: A Biotech Trading At Half Its Intrinsic Value

Company Overview

Threshold Pharmaceuticals (NASDAQ:THLD) is a developmental biopharmaceutical company focused on cancer therapeutics that target tumor hypoxia. Hypoxia (lack of oxygen) is present in almost all solid tumor cancers and is also associated with certain blood cancers. THLD's most developed drug is TH-302, which is currently being evaluated in multiple clinical studies for the treatment of soft tissue sarcoma, pancreatic cancer and a variety of other solid and hematologic tumors. TH-302 is activated under conditions of severe tumor hypoxia with the hope of being more effective in destroying tumors while minimizing toxicity to healthy tissue. THLD has patent protection for TH-302 through 2029.

Threshold has an impressive management team and board of directors with several former senior...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details